Myelodysplastic Syndromes

Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes

An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.

Combination Venetoclax Plus Azacitidine Appears Promising in High-Risk MDS or CMML

By

Jonathan Goodman, MPhil

Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.

Prolonged Isolated Thrombocytopenia After HSCT Has Prognostic Value in Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

Researchers sought to determine whether prolonged isolated thrombocytopenia impacted survival in patients with MDS.

Differences in Cytopenia in MDS May Be Related to Genetic Mutations

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether there were differences in cytopenia and other factors in patients with MDS or MPN.

Online Educational Program Improves Patient Understanding in Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether an online educational program regarding myelodysplastic syndromes would provide benefits to learners’ understanding of MDS.

Fibrinogen May Be Associated With Poor Prognosis in Myelodysplastic Syndrome

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine the role of fibrinogen levels in patients with myelodysplastic syndrome.

Post-Transplantation Prognostic Model Developed for Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to develop a clinical risk model for predicting survival outcomes with allogeneic transplantation in patients with MDS.

TP53 Mutations Predict Poor Outcomes in Patients With MDS or AML With Complex Karyotype

By

Jonathan Goodman, MPhil

Researchers sought to determine whether TP53 mutations would be linked with more aggressive disease in patients with MDS or AML.

Pretreatment Peripheral Blood Inflammatory Indices May Have Prognostic Value in Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Researchers sought to determine whether elevated platelet-to-lymphocyte ratio and plasma C-reactive protein level would help predict prognosis for patients with MDS.

Longer Azacitidine Schedule Delayed Transformation to Leukemia in Patients With MDS

By

Jessica Nye, PhD

A head-to-head comparison of 7-day and 5-day treatment schedule of azacitidine in patients with higher risk myelodysplastic syndromes revealed trends in overall survival and time to transformation to leukemia.

Optimizing Outcomes in Low-Risk Myelodysplastic Syndromes

By

Lauren Burke

Diagnosis, goals of care, and treatment options for MDS are discussed in a presentation at 2022 ONA Summit.

TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes: Is Transplant Effective?

By

Jonathan Goodman, MPhil

Researchers are trying to determine the optimal treatment strategy among patients with TP53-mutated AML or MDS.

Lower Apolipoprotein A1 Prognostic for Worse Outcomes in Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether levels of apolipoprotein A1 would be prognostic for disease outcomes in patients with MDS.

Features and Outcomes in Myelodysplastic Syndrome, Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis

By

Vicki Moore, PhD

Researchers sought to characterize features and outcomes specific to patients with MDS and MPNs with ring sideroblasts and thrombocytosis.

Features Related to Failure to Reach Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to identify features related to failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.

CADM1 Tumor Suppressor Gene Identified as Candidate Gene in Myelodysplastic Syndromes With Del(11q)

By

Lauren Dembeck, PhD

Researchers sought to determine whether the tumor suppressor gene CADM1 would be a factor influencing MDS with del(11q).

Tamibarotene Gets Orphan Drug Status for Myelodysplastic Syndrome

By

Brian Park, PharmD

Tamibarotene is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist.

Features and Treatment for Iron Overload in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to define the features and treatments for iron overload in patients with transfusion-dependent myelodysplastic syndrome.

Geno-Clinical Decision Model Accurately Predicts Diagnosis of Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Researchers sought to determine whether a machine learning-based model would be able to accurately predict the diagnoses of myeloid malignancies.

Nonablative Chemotherapy Paired With Novel T-Cell Therapy Appears Safe and Effective in Older Patients With AML and MDS

By

Lauren Dembeck, PhD

Researchers sought to determine whether nonablative chemotherapy followed by HLA-mismatched allogeneic T-cell infusion would be safe and effective in older patients with AML or MDS.

PARP1 Represents a Promising Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Researchers sought to determine the role of PARP1 in the physiological and pathological effects in MDS and AML.

How Can Lifestyle Factors Affect Myeloproliferative Neoplasms?

By

Steve Fiorillo

As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?

Features of TERT Rare Variants in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine the effects of TERT rare variants in patients with myelodysplastic syndrome.

Predicting Post-Transplant Disease Progression in Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine whether detecting MRD with mutational analysis and FCM may aid in predicting disease progression following myeloablative allo-HSCT in patients with MDS.

Allogeneic Hematopoietic Stem Cell Transplantation Negates Poor Outcomes in Myelodysplastic Syndrome With Myelofibrosis

By

Vicki Moore, PhD

Researchers sought to determine whether allo-HSCT would negate poorer outcomes in patients with MDS who have myelofibrosis.

Safety of a Bispecific Antibody in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

By

Lauren Dembeck, PhD

Researchers sought to determine whether APVO436 would have a favorable safety profile in treating patients with relapsed/refractory AML or MDS.

Role of Bone Marrow Microenvironment in Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

Researchers sought to determine how the bone marrow microenvironment contributes to the etiology of myelodysplastic syndrome.

Current and Future Perspectives of Precision Medicine in Patients With Myelodysplastic Syndromes

By

Patricia Chaney

Researchers sought to review the current understanding and available treatments of myelodysplastic syndromes as well as future perspectives.

Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?

By

Tom Greenhalgh

As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?

Possible Response Biomarkers Identified in Non-Del(5q) Lower-Risk Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers seek to identify biomarkers that may be predictive of erythroid response in patients with lower-risk myelodysplastic syndromes without a chromosome 5q deletion.

Differences in Myelodysplastic Syndromes Treatment Guidelines Do Not Account for Variable Treatment Decisions

By

Jonathan Goodman, MPhil

Researchers sought to determine whether differences in treatment guidelines for MDS would account for nonadherence to expert guidance.

Leukemic Transformation in Patients With Myelodysplastic Syndrome With Myelofibrosis

By

Vicki Moore, PhD

Researchers sought to identify inflammation-related genes that may be associated with leukemic transformation in patients with MDS with myelofibrosis.

EU Approves Luspatercept for Select Patients With Myelodysplastic Syndrome or Beta-Thalassemia

By

Patricia Chaney

Researchers sought to review the EU’s marketing authorization for luspatercept to treat select patients with MDS or transfusion-dependent beta thalassemia.

IRF4 Gene Expression Associated With Development of Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

Patricia Chaney

Researchers sought to determine whether IRF4 expression is associated with an increased susceptibility to de novo AML and myelodysplastic syndrome.

Disease Features in Young Patients With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.

Lower Mutation Burden With Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Patients With Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.

Study Shows Link Between Soluble CD40 Ligand and Tumor Necrosis Factor α in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine whether there is a link between exposure to a soluble CD40 ligand (sCD40L) and expression of TNFα in bone marrow mononuclear cells from patients with MDS.

MRI, DECT Best for Detection of Iron Content in Patients With Myelodysplastic Syndrome

By

Vicki Moore, PhD

Researchers sought to determine what is the best method for detecting liver iron abundance in patients with MDS.

Plant-Derived Compound May Have Antitumor Activity in Myelodysplastic Syndromes

By

Vicki Moore, PhD

Researchers sought to determine whether an HSP90 inhibitor and a plant-derived coumarin would have antitumor effects in patients with MDS.

Epigenetic Analysis Outlines Factors Predicting HMA Response in MDS, AML

By

Jonathan Goodman, MPhil

Researchers sought to determine what factors may help predict what patients with MDS or AML would respond to treatment with azacitidine.

HFE Mutations Have Unknown Impact on Outcomes for Patients With Myelodysplastic Syndromes

By

Jonathan Goodman, MPhil

Researchers evaluated the rates and significance of HFE variants in a population of patients with MDS.

Paroxysmal Nocturnal Hemoglobinuria Clones Positive Predictor in Myelodysplastic Syndromes, Aplastic Anemia

By

Patricia Chaney

Researchers sought to determine whether paroxysmal nocturnal hemoglobinuria clones might predict treatment responses for patients with MDS and aplastic anemia.

Older Patients With MDS Have Survival Benefit From Transplantation

By

Patricia Chaney

Researchers assessed if older patients with high-risk myelodysplastic syndrome experience significant overall survival benefit from hematopoietic transplantation.

Analysis of the Prognostic Value of the Fibrinogen-Albumin Ratio Index

By

Vicki Moore, PhD

A new study evaluated the prognostic value of the Fibrinogen-Albumin Ratio Index in certain conditions.

Patients With CCUS and Morphologic Dysplasia May Be at Greater Risk for MDS Transition

By

Jonathan Goodman, MPhil

A team of researchers sought to determine whether morphologic dysplasia may serve as a biomarker of risk for transition to myelodysplastic syndrome in patients with clonal cytopenia of undetermined significance.

Mortality Risk With COVID-19 in Patients With Myeloproliferative Neoplasms

By

Vicki Moore, PhD

Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.

Combination Treatment With p53 Reactivator Yields High Clinical Response in TP53-Mutant Myelodysplastic Syndromes

By

Lauren Dembeck, PhD

A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.

Durable Erythroid Response With Lenalidomide, Epoetin Alfa in Refractory Myelodysplastic Syndromes

By

Vicki Moore, PhD

A phase 3 trial suggests higher responses when epoetin alfa is added to lenalidomide in treatment of erythropoietin-refractory myelodysplastic syndromes.

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

By

Christina Bennett, MS

Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.

Greater KIAA0125 Expression Is Poor Prognostic Factor for Myelodysplastic Syndrome

By

Patricia Chaney

Among patients with myelodysplastic syndrome, long noncoding RNA KIAA0125 may predict poorer overall survival and leukemia-free survival.

Immune Checkpoint Inhibitor Combination Therapy Promising for AML, MDS

By

Patricia Chaney

Researchers reviewed the challenges and future developments in ICI combination therapies for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromes.